Table I.

Relevance of PYK2 for human sperm motility during capacitation.

	VAP	VCL	VSL	ALH	LIN	STR	% Motility	% Progressive motility	% Hyperactivation
C	53.8 ± 2.4	85.2 ± 2.3	47.2 ± 2.5	4.1 ± 0.1	52.6 ± 1.8	82.8 ± 1.2	97.2±0.2	68.3±2.4	12.2±2.4
⊖ Ca2+	24.5 ± 1.3*	53.2 ± 6.1*	15 ± 1*	2.9 ± 0.1*	29.2 ± 1.6*	58.9 ± 0.6*	94.8±0.3	15.5±1.9*	1.6±0.3*
PF 10 µM	34.5 ± 3.4*	59.2 ± 2.6*	28.1 ± 2.8*	3.1 ± 0.1*	43.3 ± 3.9	73.9 ± 3.5	97.2±0.2	39.9±7.4*	2.5±0.6*
PF 30 µM	29.0 ± 2.5*	54.9 ± 2.9*	21.3 ± 2.5*	3.2 ± 0.1*	35.6 ± 1.8*	66.8 ± 1.7*	94.6±1.1	25±4.5*	2.4±0.4*

Computer-assisted sperm analysis was performed in sperm incubated for 18 h in BWW (C), or in BWW without added Ca²⁺ (⊖ Ca²⁺) or in BWW containing the FAK/PYK2 inhibitor PF431396 (PF 10 µM or 30 µM). VAP, average path velocity; VCL, curvilinear velocity; VSL, straight line velocity; ALH, amplitude of lateral head displacement; LIN, linearity; STR: straightness (n = 4). Statistical significance of the data was analyzed using one-way analysis of variance. *versus C, P < 0.05.